Taktile Launches Data Marketplace with Leading Data Providers to Empower Lenders
9.5.2023 12:01:00 EEST | Business Wire | Press release
Taktile, the leading automated decisioning platform, announced the launch of its Data Marketplace as part of its mission to revolutionize how fintechs and banks harness data to make decisions.
The Taktile Data Marketplace is a one-stop ecosystem of leading data providers that enables customers to easily access a global collection of traditional credit, identity, fraud, accounting, open banking, and alternative data sources. By leveraging these data sources, Taktile customers can refine their credit policies and automated decision flows to better identify the right customers and make smarter, more accurate decisions that support profitable growth.
Supported data integrations include: Codat, CRS, NovaCredit, Boniversum, credolab, LexisNexis, Experian, Transunion, Equifax, Creditreform and Belvo.
“Identifying the right data sources for your customer segment has never been more important, but building data integrations in-house is often painful, time-consuming, and resource-intensive,” explained Taktile Co-Founder and CEO Maik Taro Wehmeyer. “Our Data Marketplace makes it easy for risk experts to experiment with various data sources so they can focus on improving their decision accuracy rather than on building integrations.”
On Taktile’s low-code platform, fintechs and traditional financial institutions can easily add new data sources from around the world in minutes through using Taktile’s pre-built integrations that support both B2B as well as B2C use cases. In addition, Taktile already offers functionality today that enables customers to easily connect to any modern third-party API so that users are not constrained by the current offering of off-the-shelf integrations.
The obtained data is well-structured and organized, making it easy to glean aggregate insights, build custom metrics, and identify the right KPIs that take decision accuracy to the next level. Users can also simulate decision outcomes before setting new decision strategies live, empowering them to make informed decisions based on real evidence not speculation.
At a time when profitability is top of mind for fintechs and financial institutions, simplifying data integrations is a powerful advantage. Through rapid experimentation, Taktile customers can uncover the best data sources for their target population and ultimately increase acceptance rates, lower default rates, and offer competitive risk-based pricing–all without requiring any engineering resources.
“In a challenging market, it is lenders' ability to harness data to build the most comprehensive view of their borrowers that gives them the edge,” said Phil Low, Head of Partnerships at Codat. "Now that Codat’s universal API is part of Taktile’s Data Marketplace, Taktile customers can incorporate data from any major accounting, open banking or commerce system into their decisioning engine in a few simple steps. In other words, obtaining that edge just got a lot simpler."
The launch of the Data Marketplace reflects Taktile's commitment to innovation and its ongoing efforts to provide customers with the tools they need to succeed in today's rapidly changing business environment. As part of this commitment, Taktile will rapidly add new global data partners every month and expects to triple the number of providers by the end of the year.
About Taktile
Taktile is a rapidly-growing automated decisioning platform that is revolutionizing how companies harness data to steer their business. Taktile’s low-code platform allows companies to easily build, run and evaluate automated decision flows without requiring developers to write complex code. In a world increasingly run on automated decisions, Taktile makes it easy for credit and data teams to build more accurate decision flows, adapt to change quickly, and, ultimately, improve outcomes. Founded in 2020, Taktile has offices in New York, London and Berlin and is backed by leading VCs, including Index Ventures, Tiger Global, and Y Combinator.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230509005114/en/
Contact information
Audrey White - audrey.white@taktile.com / +44 7908 033980
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Two-Year Data of Pimicotinib Demonstrated Durable Tumor Control and Sustained Improvement in TGCT Symptoms and Joint Function26.10.2026 13:00:00 EET | Press release
Merck, a leading science and technology company, today announced new two-year follow-up results from the Phase 3 MANEUVER study evaluating pimicotinib in patients with tenosynovial giant cell tumor (TGCT). The study showed that among patients initially randomized to pimicotinib, improvements in symptoms and joint function were observed as early as Week 5, sustained through two years, and continued to improve over time. Tumor responses remained robust1 and durable,2 and the safety profile was consistent with previous analyses. The findings are being presented today in the Sarcoma poster session at the European Society for Medical Oncology (ESMO) Congress 2026 (Presentation # 3747P). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022786567/en/ David Weinreich, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck "For people living with TGCT, the impact of the disease is often felt through persis
WHOOP and Samuel Ross MBE Unveil Layer 2 of PROJECT TERRAIN26.10.2026 12:30:00 EET | Press release
WHOOP, the human performance brand, today announced Layer 2 of PROJECT TERRAIN, its multiyear collaboration with British designer Samuel Ross MBE and his design atelier, SR_A. Building on the sold out debut collection launched in March 2026, Layer 2 expands PROJECT TERRAIN to its next season connecting lifestyle and performance for movement, adaptability and zone based training. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261026029587/en/ WHOOP and Samuel Ross MBE Unveil Layer 2 of PROJECT TERRAIN While the first PROJECT TERRAIN collection harnessed dense cities and modern training grounds, Layer 2 explores performance through material, silhouette and tactility. Drawing on the textures, conditions, and flux of the natural world, the collection introduces a newly developed system of WHOOP bands, Italian technical apparel, outerwear, and accessories designed to move between urban and outdoor settings. Performance extends be
Bleeding gums? Don't ignore the warning signs – the first stage of gum disease can be reversed26.10.2026 12:28:00 EET | Press release
Gums bleeding when brushing can happen to any of us, and it is easy to ignore. But blood in the sink is a sign that something is not right with your mouth. Bleeding gums often indicate gingivitis, the earliest and most common form of gum disease. The good news: gingivitis can be reversed with proper oral hygiene. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022835650/en/ Oral-B iO Left untreated, gingivitis can progress into periodontitis, a more severe stage of gum disease that can only be managed, not reversed, and can lead to losing teeth over time. Healthy gums matter beyond the mouth, too. Oral health and systemic health are deeply interconnected, with inflammation and bacteria from oral diseases contributing to conditions such as heart disease, diabetes and dementia. "Gums bleeding when brushing can happen to any of us. When they do, it shouldn't be ignored," said Eva Castro Perea, who holds a degree in dentistry
Merz Therapeutics Presents New Phase 2 PaiNT Data in Peripheral Neuropathic Pain at IASP 202626.10.2026 09:00:00 EET | Press release
Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced the presentation of new clinical and translational research in peripheral neuropathic pain (PNP) at the International Association for the Study of Pain (IASP) 2026 World Congress in Bangkok, Thailand, taking place from 26 to 30 October. The research spans new Phase 2 findings on incobotulinumtoxinA in postherpetic neuralgia (PHN) and post-surgical/post-traumatic neuropathic pain (PS/PTNP), as well as preclinical studies exploring potential biological mechanisms involved in effects of incobotulinumtoxinA on PNP models, highlighting Merz Therapeutics’ growing presence in neuropathic pain. In the PHN population of the Phase 2 PaiNT trial, results over 20 weeks favored incobotulinumtoxinA versus placebo treatment. In an exploratory analysis of average daily pain (ADP) intensity, the greatest difference between treatment groups was observed at Week 6 (adjusted mean difference, −1.14 points; p=0.0488).
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom